Optimizing Oncology Trials To Generate High-Quality Data For Regulatory Decision-Making

The preliminary FDA directives pertaining to patient-reported outcomes measures (PROMS) within cancer trials are ushering in a paradigm shift in the blueprinting and execution of Clinical Outcome Assessment measurement approaches in the domain of oncology research.

Drawing from his profound expertise, Signant Health's Clinical Vice President of Internal Medicine, Anthony T. Everhart, MD, imparts invaluable perspectives on crafting effective measurement strategies in oncological frameworks. Furthermore, he expounds on the strategic utilization of decentralized methodologies to enhance the trial engagement journey for both patients and trial sites, thereby enriching the overall research experience.

Watch Episode 3 of Signant’s scientific video series, Clinical Viewpoints, for key takeaways from the recent FDA guidance on the use of COA and PROMS in oncology trials and other additional insights surrounding the topic.